Valeant Pharmaceuticals reported $1.79B in Gross Profit on Sales for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Amgen AMGN:US $ 5084M 407M
Aurora Cannabis Inc ACB:CN -22244000 30.69M
Biogen BIIB:US $ 2105.1M 327.2M
Bristol Myers Squibb BMY:US $ 9210M 33M
Canopy Growth Corp WEED:CN C$ -1392000 157.85M
Catalent CTLT:US $ 488M 65M
Corcept Therapeutics CORT:US $ 102.07M 9.63M
Danaher DHR:US $ 4721M 16M
Eli Lilly And LLY:US $ 5057.5M 680.4M
Gilead Sciences GILD:US $ 4818M 348M
Horizon Pharma HZNP:US $ 646.2M 23.99M
JAZZ PHA JAZZ:US $ 808.67M 110.23M
Lannett LCI:US $ 7.86M 4.78M
Nektar Therapeutics NKTR:US $ 16.47M 3.04M
Pacira Pharmaceuticals PCRX:US $ 118.78M 3.13M
Perrigo Ordinary Shares PRGO:US $ 372.1M 34.3M
Prestige Brands PBH:US $ 160.12M 11.26M
Revance Therapeutics RVNC:US $ 18.84M 1.48M
Supernus Pharmaceuticals SUPN:US $ 149.59M 15.02M
Valeant Pharmaceuticals VRX:CN $ 1789.21M 422.21M
Vertex Pharmaceuticals VRTX:US $ 1934.4M 82.7M
Zoetis ZTS:US $ 1432M 11M